BioMarin Pharmaceutical Inc. ($BMRN) Stock Forecast: Down 5.1% Today

What is BioMarin Pharmaceutical Inc.?

BioMarin Pharmaceutical Inc. (BMRN) is a biopharmaceutical company focused on developing innovative therapies for rare genetic diseases. Today, the stock experienced a strong bearish movement amidst significant news and developments in the company.

Why is BioMarin Pharmaceutical Inc. going down?

BMRN stock is down 5.1% on Jan 13, 2026 18:26

• The announcement of BioMarin Pharmaceutical's estimated 2025 revenue of $3.2 billion and the strong performance of Voxzogo at $920 million at the recent conference should have been positive news. However, the market may have reacted negatively due to concerns about the company's ability to meet these revenue targets.
• The hiring of Arpit Davé as Chief Digital and Information Officer to accelerate rare disease therapies shows the company's commitment to innovation. However, the market might have interpreted this move as a signal of potential challenges in the current R&D and commercial operations that require urgent attention.
• Despite the outlined growth strategy, pipeline progress, and Amicus integration positioning BioMarin for sustained double-digit compound annual growth rate, investors may have focused on the weak long-term outlook highlighted in the tactical trading analysis. This could have contributed to the bearish movement in the stock.
• The absence of clear long-term support signals and elevated downside risk might have spooked investors, leading to a sell-off of the stock despite the positive developments and revenue projections.

BMRN Price Chart

BMRN Technical Analysis

BMRN News

BioMarin Pharmaceutical touts $3.2B 2025 revenue, Voxzogo surge and Amicus deal at JPM Conference

BioMarin Pharmaceutical presented its strategic priorities and preliminary 2025 revenue figures at the J.P. Morgan Healthcare Conference, targeting significant growth driven by Voxzogo, its enzyme therapies, and the pending acquisition of Amicus. The company announced estimated 2025 revenue of $3.2 billion, with Voxzogo's performance particularly strong at $920 million. BioMarin also outlined upcoming regulatory and clinical catalysts for its pipeline, including a full approval filing for Voxzogo and advancements for BMN 351 and BMN 333.

https://finance.yahoo.com/news/biomarin-pharmaceutical-touts-3-2b-104622765.html

BioMarin hires AI leader to help accelerate rare disease therapies

BioMarin has appointed Arpit Davé as Executive Vice President, Chief Digital and Information Officer, effective January 12, 2026. Davé will lead the company's enterprise technology strategy, data science, and digital transformation, aiming to accelerate R&D, manufacturing, and commercial operations. With over 20 years of IT and AI experience in biopharma, including from Amgen, Bristol Myers Squibb, and Merck, his role is expected to drive innovation and support the delivery of life-changing rare disease therapies.

https://www.stocktitan.net/news/BMRN/bio-marin-appoints-arpit-dave-chief-digital-and-information-5n3ua5x9gvb5.html

BMRN: Strong growth, pipeline progress, and Amicus integration position for sustained double-digit CAGR

BioMarin Pharmaceutical Inc. (BMRN) has outlined a new growth strategy emphasizing strong revenue growth, advancements in its pipeline, and the integration of Amicus assets. The company anticipates global expansion for Voxzogo and expects significant data and regulatory milestones for various programs between 2024 and 2026. This strategy positions BMRN for sustained double-digit compound annual growth rate.

https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:2586382:0-bmrn-strong-growth-pipeline-progress-and-amicus-integration-position-for-sustained-double-digit-cagr/

Biomarin Pharmaceutical Inc estimates $3.2 billion in total revenues for FY - SEC filing

BioMarin Pharmaceutical Inc. has estimated its total revenues for the current fiscal year to be $3.2 billion, according to an SEC filing. This financial outlook provides key information for investors and stakeholders. The company also announced the appointment of Arpit Dave as Chief Digital and Information Officer on the same day.

https://www.marketscreener.com/news/biomarin-pharmaceutical-inc-estimates-3-2-billion-in-total-revenues-for-fy-sec-filing-ce7e58dbd988f727

Why (BMRN) Price Action Is Critical for Tactical Trading

This article analyzes Biomarin Pharmaceutical Inc. (NASDAQ: BMRN) for tactical trading, noting strong near and mid-term sentiment but a weak long-term outlook. It highlights the absence of clear long-term support signals, indicating elevated downside risk. The report provides AI-generated trading strategies—position, momentum breakout, and risk hedging—along with multi-timeframe signal analysis, including support and resistance levels.

https://news.stocktradersdaily.com/news_release/139/Why_BMRN_Price_Action_Is_Critical_for_Tactical_Trading_011026093601_1768055761.html

Trending Today

BlackLine, Inc. ($BL) Stock Forecast: Up 5.1% Today

Crowdstrike Holdings Inc. ($CRWD) Stock Forecast: Up 5.0% Today

Chewy Inc ($CHWY) Stock Forecast: Up 5.1% Today

International Paper Company ($IP) Stock Forecast: Up 5.8% Today

Coupang LLC ($CPNG) Stock Forecast: Up 5.1% Today

Oracle Corporation ($ORCL) Stock Forecast: Up 5.1% Today

Aurora Cannabis Inc. ($ACB) Stock Forecast: Up 5.0% Today

Corebridge Financial ($CRBG) Stock Forecast: Up 5.2% Today

Intel Corporation ($INTC) Stock Forecast: Up 5.2% Today

Palantir Technologies Inc ($PLTR) Stock Forecast: Up 5.3% Today

BioMarin Pharmaceutical Inc. Price History

13.00.2026 - BMRN Stock was down 5.1%

• The announcement of BioMarin Pharmaceutical's estimated 2025 revenue of $3.2 billion and the strong performance of Voxzogo at $920 million at the recent conference should have been positive news. However, the market may have reacted negatively due to concerns about the company's ability to meet these revenue targets.
• The hiring of Arpit Davé as Chief Digital and Information Officer to accelerate rare disease therapies shows the company's commitment to innovation. However, the market might have interpreted this move as a signal of potential challenges in the current R&D and commercial operations that require urgent attention.
• Despite the outlined growth strategy, pipeline progress, and Amicus integration positioning BioMarin for sustained double-digit compound annual growth rate, investors may have focused on the weak long-term outlook highlighted in the tactical trading analysis. This could have contributed to the bearish movement in the stock.
• The absence of clear long-term support signals and elevated downside risk might have spooked investors, leading to a sell-off of the stock despite the positive developments and revenue projections.

19.11.2025 - BMRN Stock was up 7.7%

• The appointment of Rashmi Ramchandani as the new chief accounting officer brings fresh leadership to BioMarin, potentially signaling positive changes within the company.
• Despite concerns about cost-cutting measures and pipeline shifts, investors seem optimistic about BioMarin's future growth prospects, particularly with the Inozyme acquisition and the focus on rare disease treatments.
• The selling of shares by Hudson Bay Capital Management LP and Bellevue Group AG may have initially raised some eyebrows, but the increased holdings by other institutional investors like Dodge & Cox and Viking Global suggest confidence in BioMarin's long-term potential.
• Overall, the market's bullish response to BioMarin today could be attributed to a combination of new leadership, strategic acquisitions, and investor confidence in the company's ability to navigate through its current transformation phase successfully.

15.11.2025 - BMRN Stock was down 2.1%

• Hudson Bay Capital Management LP, Bellevue Group AG, and other institutional investors have decreased their stakes in BioMarin Pharmaceutical Inc., possibly indicating concerns about the company's immediate performance outlook.
• Despite falling short of quarterly earnings per share (EPS) estimates, BioMarin's positive guidance for FY2025 and ongoing restructuring efforts have generated optimism among investors. This is evidenced by increased holdings from Dodge & Cox, Viking Global, AQR, Geode, Norges Bank, and Boone Capital Management LLC.
• The market's response to the mixed signals of underperforming earnings but promising future projections implies that investors are considering the company's current obstacles against its growth potential and margin expansion through restructuring and late-stage trials.
• The fluctuation in BioMarin's stock price today results from a combination of short-term profit-taking by some investors and long-term confidence stemming from the company's strategic initiatives and advancements in its pipeline.

16.08.2024 - BMRN Stock was down 8.2%

• The bearish movement in BMRN today may be linked to Ascendis Pharma's positive trial results for a dwarfism treatment, potentially impacting BioMarin's Voxzogo.
• Investors are likely concerned about BioMarin's market share in light of this news.
• Competition in the rare disease drug market is intense, with positive developments from rivals often affecting stock prices.

08.03.2025 - BMRN Stock was down 6.0%

• Today's downward trend in BMRN could be a result of investors taking profits following a period of positive developments and possible overvaluation.
• While the Phase 3 trial results for Palynziq in adolescent patients were encouraging, some investors may have anticipated even better outcomes, leading to selling pressure.
• Comparisons to CSL Limited in terms of valuation might have influenced investor attitudes, prompting some to reconsider their investment allocations in pursuit of perceived better opportunities.
• In conclusion, today's market behavior for BMRN appears to reflect a mix of profit-taking, unmet high expectations, and potential shifts in investor preferences within the sector.

15.00.2025 - BMRN Stock was down 5.3%

• Despite positive projections from financial analysts, BioMarin (BMRN) faced a notable decline in its stock value recently.
• The difference between the optimistic forecasts and the current market performance may be linked to general market sentiment, investor profit-taking, or unexpected negative developments impacting the company.
• Investor response to external factors like regulatory challenges, unsatisfactory clinical trials, or overall market instability likely contributed to the recent drop in BioMarin's stock value.

08.00.2025 - BMRN Stock was up 1.4%

• Investors have been analyzing BMRN alongside TECH to evaluate their investment potential.
• This comparison likely piqued investor interest in BMRN, resulting in heightened buying activity and the observed bullish trend.
• Trader sentiment regarding the relative value of BMRN compared to TECH may have prompted increased bullish positions on BMRN in today's trading session.

06.07.2024 - BMRN Stock was up 8.0%

• BioMarin stock surged following better-than-expected Q2 results, with earnings per share of 96 cents exceeding analyst forecasts.
• Despite a target reduction by TD Cowen, the stock maintained a Buy rating, indicating optimism regarding the company's performance.
• The affirmation of progress and increased full-year guidance during the earnings call bolstered investor confidence in BioMarin's future outlook.
• A robust earnings report, demonstrating revenue of $712.03 million, outpacing analyst predictions, contributed to the positive momentum in BMRN stock.

04.03.2025 - BMRN Stock was down 10.4%

• Despite positive Phase 3 results for Palynziq in lowering blood Phe levels in adolescents, BioMarin's stock saw a bearish trend.
• The market may have reacted negatively due to profit-taking by investors after a recent run-up in the stock price following the positive results.
• Investors might be concerned about the timeline and potential challenges in getting label expansion approval from health authorities despite the promising data.
• The bearish movement could also be influenced by broader market conditions or sector-specific factors impacting biotechnology stocks.

06.07.2024 - BMRN Stock was up 5.4%

• Better-than-expected second-quarter financial results were reported by BioMarin Pharmaceutical, with earnings per share of 96 cents, surpassing the analyst consensus estimate of 35 cents per share.
• The company confirmed progress and raised its full-year guidance, indicating positive momentum and growth prospects.
• The market reacted positively to the earnings beat and optimistic outlook, driving the bullish movement in BMRN stock as investors gained confidence in the company's performance and future potential.

20.01.2025 - BMRN Stock was up 6.3%

• BioMarin's Q4 adjusted EPS exceeding consensus expectations and providing strong sales guidance for 2025 has fueled investor confidence in the company's growth prospects.
• The positive earnings report and future outlook have likely attracted new investors and increased buying interest in the stock.
• The market's reaction indicates that investors are optimistic about BioMarin's ability to deliver on its financial targets and continue its success in developing treatments for rare diseases.

29.09.2025 - BMRN Stock was down 3.3%

• Analysts revised their forecasts for BioMarin Pharmaceutical following lower-than-expected earnings reported for the third quarter.
• Earnings for the quarter were 12 cents per share, missing the analyst consensus estimate of 37 cents per share.
• The unsatisfactory earnings likely shook investor confidence, leading to a bearish movement in the stock price.
• Investors may be worried about the company's future performance and its impact on its pipeline of therapies for rare genetic diseases.